Ranibizumab for treating diabetic macular oedema

Technology appraisal guidance
Reference number: TA274
Published: 27 February 2013
Last updated: 26 October 2023

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): CSAS
04 January 2013
(107.58 Kb 31 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 28 December 2012